Welcome to our dedicated page for Global Innovative Platforms SEC filings (Ticker: GIPL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Global Innovative Platforms's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Global Innovative Platforms's regulatory disclosures and financial reporting.
Global Innovative Platforms Inc. filed a notice that its Annual Report on Form 10‑K for the year ended September 30, 2025 will be submitted late. The company states it needs additional time for compilation and review to ensure adequate disclosure of required information in the 10‑K.
Under Rule 12b‑25, the company expects to file the Form 10‑K on or before the 15th calendar day following the prescribed due date, which keeps the filing within the allowed extension window.
Global Innovative Platforms Inc. reported that it has posted an updated investor presentation and shared preliminary scientific results on its VOCAM Plus breath-analysis technology for canine heartworm detection. The company used artificial intelligence and multivariate statistical tools to analyze breath samples from dogs with and without confirmed heartworm and found measurable differences between infected and non‑infected animals.
The study suggests a consistent breath VOC profile associated with heartworm, including in many samples classified as early-stage infection, a phase where current antigen tests cannot yet detect disease for roughly the first six months. In an internal self-prediction test of its model, there was only one misclassification, in which an early heartworm sample was labeled as mature. When the model was applied to the full dataset, trimmed samples did not incorrectly fall into any of the three modeled states. The company plans to continue testing and confirming these early but encouraging findings.
Global Innovative Platforms Inc. (GIPL) filed an 8-K announcing two developments. The company entered into an agreement with a global animal health company to evaluate and validate its proprietary VOCAM Plus breathomics diagnostic technology for detecting heartworm disease in dogs. The company will supply VOCAM Plus units and related support services for this evaluation, with the full agreement to be filed with the next Form 10-K.
The Board changed auditors. On November 3, 2025, it dismissed M. S. Madhava Rao, Chartered Accountant, and appointed CNGSN & Associates LLP as the independent registered public accounting firm for the fiscal year ending September 30, 2025. The prior auditor’s reports for fiscal years 2024 and 2023 contained no adverse opinions or disclaimers, and the company reports no disagreements or reportable events. A letter from the former auditor dated November 6, 2025 is filed as Exhibit 16.1.
Global Innovative Platforms (GIPL) insider Andrew N. Brown, who serves as CEO, CFO and Director and is a 10% owner, reported multiple transactions on Form 4. Reported activity includes open-market purchases at $0.0017 per share, such as 250,000 shares on 09/30/2025 and 273,000 shares on 07/03/2025, plus a gift of 50,416 shares on 06/30/2025. Following these transactions, he directly beneficially owned 10,310,554 shares as shown after the 09/30/2025 entry.